The viral antigens trigger a tumor-specific T-cell response that shapes a favorable immune contexture for the response to standard therapy. Hence, reinforcement of HPV16-specific Tcell reactivity is expected to boost this process.
Introduction
The incidence of oropharyngeal squamous cell cancer (OPSCC) is rising, especially in younger adults (1) . Classically the development of OPSCC is related to p53 mutations, but currently more than half of all OPSCC are caused by a high-risk human papillomavirus, most often type 16 (HPV16) (1) . Although HPV-associated OPSCC are more often diagnosed with TNM stage III-IV, consisting of an earlier T stage and more advanced N stage, than HPV-negative OPSCC (2), they display a much better prognosis than HPV-negative tumors after (chemo)radiation therapy. This is independent of many common histopathological parameters (2, 3) , but associated with the presence of a strong adaptive immune response gene signature (4) and dense tumor infiltration by activated CD4+ and CD8+ T-cells (3, 5, 6) , suggesting a role for the adaptive immune system in the response to therapy.
Notably, HPV-associated OPSCC express viral proteins and we have shown that they may function as tumor-specific antigens for OPSCC-infiltrating T-cells (7) . Clear evidence for a protective role of tumor-infiltrating HPV-specific T-cells in OPSCC, however, is lacking. Hence, it is important to evaluate if HPV-positive OPSCC are commonly infiltrated by HPV-specific T-cells, and specifically, how this pertains to the composition of the tumor microenvironment and survival. We purely focused on the analysis of HPV-specific T-cell reactivity within the tumor-infiltrating lymphocyte (TIL) population since detection of circulating HPV-specific T-cells might reflect a response to past infections (8) , potentially even in other anatomical locations (8) and, thus, less relevant to our study.
In case of such a relation, reinforcement of HPV-specific T-cell reactivity becomes highly attractive for treatment of OPSCC.
Materials and methods

Patients
Patients with histological confirmed OPSCC were included after signing informed consent.
This study is part of a larger observational study P07-112 (7) , approved by the local medical ethical were taken prior to treatment and handled as described previously (9) and in Supplementary Methods. Peripheral blood mononuclear cells (PBMCs) and tumor infiltrating lymphocytes (TILs) were stored until use. HPV typing and p16 ink4a immunohistochemical staining was performed on former fixed paraffin embedded (FFPE) tumor sections at the department of pathology at the LUMC.
Immunofluorescent staining of FFPE tumor sections for CD8 and Tbet was performed as described previously (10) and in Supplementary Methods. The patients received the standard-of-care treatment which could consist of surgery, radiotherapy, chemotherapy, treatment with monoclonal antibody or combinations hereof. Staging of the tumor was done according to the National
Comprehensive Cancer Network (https://www.nccn.org/ professionals). Patient characteristics are given in Supplementary Table S1 .
Cancer cell lines.
The OPSCC cell lines were obtained from the University of Michigan (Ann Arbor, MI, USA) and called UM-SCC. We obtained UM-SCC4 (passage 22), UMC-SCC6 (passage 33), UM-SCC19
(passage 17) (all three HPV negative), and UM-SCC47 (passage 98) and UM-SCC104 (passage 15)
(both HPV16-positive) in 2012. The cells were cultured in RPMI 1640 (Gibco/ Thermo Fisher Scientific (TFS) Bleiswijk, the Netherlands) with 10% Fetal Calf Serum (PAA laboratories; Pashing, Austria) and penicillin/streptomycin (TFS). Tumor cell supernatant (TSN) was prepared after 5 days of culture as described previously (11) . Microsatelite analysis was performed in July 2016 by BaseClear (Leiden, the Netherlands) to assure cell line authentication when the experiments were performed.
Mycoplasma was tested on a monthly basis.
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T-helper clones.
Clonal dilution was performed using the TILs from patient H68 as described previously (7) .
Their HPV specificity and cytokine production was determined. This resulted in multiple CD4+ Thelper (Th) cell clones of which Th1 (clones 78 and 97), Th2 (clone 133) and Th17 (clones 12 and 103)
were selected for the experiments. T-cell supernatant was obtained after stimulation with cognate HPV peptide loaded on with EBV immortalized B cells for 3 days.
TIL and tumor cell analyses
The phenotype and composition of dispersed tumors (and expanded TILs) was analyzed by flow (9, (12) (13) (14) (15) and time of flight mass cytometry (CyTOF) (16) (Supplementary Methods). Supplementary Table S2 shows the 36 markers used for CyTOF analysis. The reactivity of TILs was determined in a 5-days proliferation assay (9) and by intracellular cytokine staining (15) . Supernatant from the proliferation test were subjected to cytokine analysis (15) . The effect of TSN on DC differentiation was determined phenotypically and functionally (cytokine/chemokine production) upon LPS or agonistic CD40 antibody stimulation in presence or absence of INF as described previously (11, 13) and in Supplementary Methods. Biovision, Milpitas, CA, USA) was added to the conditions used for UM-SCC19 to inhibit necroptosis via inhibition of RIP1K (14) . The treated tumor cells were harvested and subjected to SYTOX green staining to establish the percentage of dead cells and in parallel stained for flow-based apoptosis analysis using Annexin V (early apoptosis) and 7-AAD (late apoptosis). As indicated tumor cells were also analysed for RNA expression (quantative PCR) (14) and protein content (western blot) (14) (See also Supplementary Methods).
Statistical analysis
Unpaired parametric t test was used to determine the difference between various treatments of the cells from the UM-SCC tumor cell lines. Date of two groups of patients were analyzed using the unpaired non-parametric analysis (Man Whitney). Fisher Exact test was used to analyze categorical data in a contingency table. Data of the three groups of patients (p16-IR-; p16+IR-; p16+IR+) were analyzed using the unpaired non-parametric one-way ANOVA (Kruskal Wallis). Hazard ratio (HR) with a 95% confidence interval (CI95%) was calculated to determine the difference in survival curves. The non-parametric log-rank test (Mantel-Cox test) was done to compare the survival distribution of the two group of patients. In all cases a P-value of 0.05 and below was considered significant (*), P<0.01 (**) and P<0.001 (***) as highly significant.
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Results
The majority of HPV16-positive OPSCC contain HPV16-specific Th1/Th17 cytokine producing T-cells
To interrogate the role of HPV-specific T-cells in OPSCC we prospectively assembled a cohort of 97 patients with OPSCC, 57 of which were HPV16 positive. Analysis of the patient characteristics showed the expected percentage of HPV-positive patients (2, 3) and the differences in smoking, Nstage and disease specific survival when compared to HPV-negative OPSCC (Fig. 1A , Supplementary Table S1 ), indicating that our patient cohort does not differ from those reported in literature.
From each patient both freshly obtained and FFPE tumor material was stored ( Supplementary Fig. S1 ). The presence, proliferation and cytokine production of HPV16-specific and other OPSCC-infiltrating T-cells in the dissociated OPSCC were analyzed either directly or following a 2-4 weeks expansion period ( Supplementary Fig. S1 ). Reactivity to the HPV16 E6 and/or E7 oncoproteins was detected directly ex-vivo in 6 out of 24 samples, and in 29 of 45 of the expanded TIL HPV16-positive cases. All directly ex-vivo detectable responses were confirmed in the expanded TIL. None of the 23 tested TIL cultures obtained from HPV-negative tumors displayed HPV-specific reactivity ( Fig. 1B and 1C) , showing the specificity of these type of TIL analyses (7) and demonstrating that HPV-specific T-cells only infiltrate HPV+ OPSCC.
Subsequently, supernatants taken from the HPV-reactive cultures were assessed for the presence of Th1 (IFN, TNF, IL-2), Th2 (IL-4, IL-5, IL-10), and Th17 (IFN, IL-17) cytokines revealing a Th1/Th17 like profile (Fig. 1D) . Flow cytometry analysis demonstrated that the population of activated and/or cytokine producing HPV-specific T-cells frequently comprised both CD4+ and CD8+ HPV-specific T-cells ( Fig. 1E and Supplementary Fig. S2 ), which targeted multiple epitopes simultaneously (Fig. 1F) , albeit that the percentage of HPV-specific cytokine producing CD4+ T-cells often was higher than that of CD8+ T-cells (Fig. 1G) . Thus, the majority of HPV16-positive OPSCC tumors are infiltrated by HPV16-specific CD4+ and CD8+ T-cells with a Th1/Th17 profile. Fig. S3A ). Furthermore, tobacco smoking and in particular nicotine is known to impair the responsiveness of T-cells to antigenic stimulation (21). While there were many patients with more than 10 pack years of smoking (2) ( Supplementary Fig. S3B ), this was not discriminative for the detection of HPV16-specific immunity ( Supplementary Fig. S3C ). Hence the failure to produce a T-cell reaction to HPV in HPV16-positive OPSCC most likely is due to the limited quantities of viral proteins available to the immune system. Fig. S4 ).
Research. The production of IFN and IL-17 was lower in the p16+ IR-and the p16-IR-group. Moreover, the production of IL-5 was increased in the latter two groups suggesting a shift towards a more type 2 cytokine profile.
In addition, we quantified the number of type 1 polarized immune cells in the HPV16-positive tumors using immunohistochemistry for CD8 and the with IFN-production associated T-box transcription factor TBX21 (Tbet). The numbers of tumor-infiltrating Tbet+CD8+ T-cells and Tbet+CD8-negative T-cells, based on our flow cytometry data most likely CD4+ T-cells, correlated with an improved survival ( Fig. 2A) and were particularly high when the OPSCC contained HPVspecific T-cells (Fig. 2B ).
To comprehensively analyze the composition and phenotype of intratumoral immune cells directly ex-vivo, a validated panel of 36 antibodies adapted from a previous study (16) (Supplementary Table S2 ) was used in combination with mass cytometry (CyTOF) in 13 freshly dissociated OPSCC. This showed that the HPV16-positive OPSCC from HPV16 immune responder patients were stronger infiltrated with CD4+ and CD8+ T-cells ( Fig. 2C and 2D ) carrying an effector memory phenotype (Fig. 2E) , whereas the HPV16-positive OPSCC in which no HPV16-specific T-cell reactivity was detected, displayed a strong influx with B cells (Fig. 2D) . NK cells, which may also infiltrate tumors and express Tbet, were virtually absent (Fig. 2D) . In order to automatically discover stratifying biological signatures we used the CITRUS algorithm with a false discovery rate (FDR) of 1% resulting in 5 distinctive (groups of) populations of immune cells (Fig. 2F) . It confirmed the differences in the percentages of tumor-infiltrating B cells and T-cells (Fig. 2G ), but also revealed the presence of three subsets of T-cells that were present at significantly higher levels in HPV16 immune responders (Fig. 2H) . Inspection of these subsets revealed two subsets of activated CD4+ T-cells and a subset of tissue-resident effector memory CD8+ T-cells expressing CD103 ( Supplementary Fig. S5A and S5B). The two subsets of activated CD4+ T-cells expressed CD38, HLA-DR and PD1 but were separated on the basis of CD161 expression (Supplementary Fig. S5A and S5B). The CD161-negative subset of activated CD4+ T-cells had a high expression of CD25 but also expressed CD127, whereas Fig. S6C ). In addition, the co-stimulatory molecules were upregulated.
Thus, the infiltration of OPSCC by HPV16-specific Th1/Th17 cells is associated with the presence of highly active tumor microenvironment consisting of a dense type 1 oriented immune cell infiltrate, known to favor immune-mediated control of cancer cells (29).
Type 1 cytokines influence tumor cell proliferation and synergize with cisplatin-induced cell death
The OPSCC-infiltrating HPV-specific CD4+ T-cells produced IFN and TNFknown to drive tumor cell senescence (30) and to synergize with platinum-based therapy to kill tumor cells (31). We, Fig. S8A ). Subsequently, a flow cytometric analysis of 8 in vitro expanded TILs was performed to assess the HPV-specific component among these cells. On average the percentage of CD161+ CD4+ T-cells was 29% (Fig. 5A) . The number of HPV-specific T-cells producing TNF (Fig. 5B ) was a bit higher than those producing IFN ( Supplementary Fig. S8B ) and on average 31% of the HPV-specific CD4+ T-cells expressed CD161 (Fig. 5B ). This indicates that there was a sizeable CD161+ T-cell fraction among HPV-specific CD4+ T-cells in most of the patients and also that the distribution of CD161+ cells among these HPV-specific T-cells is similar to that of the total population. Subsequently, we analyzed the survival of the 75 patients with HPV16-positive OPSCC in the publicly available TCGA database focusing on the expression of CD4, CD8, CD103 and CD161. A high expression of CD4, CD8 or CD161 was associated with better overall survival but this was not the case for CD103 expression (Fig. 5C-5F ), albeit that the combined high expression of CD103 with CD8 resulted in a better segregation of the survival curves (Fig. 5G ). This fits with the observation that the expression of CD8 and CD103 was not strongly correlated (r = 0,2559; P = 0 .0267) within this cohort.
A high expression of CD161 with either high CD4 or CD8 expression was also associated with better survival ( Fig. 5H and 5I) . Notably, the populations of patients within the group seem to overlap completely. Indeed, these markers were highly co-expressed (CD4 and CD161: r = 0,8351; P = 0.00E00, and CD8 and CD161: r = 0.8363 ; P = 0.00E00), suggesting that they predominantly single out the same patients. Since the HPV-specific T-cells predominantly produced IFN, TNF and IL-17 (Fig. 1D) we also analyzed the contribution of the respective gene expression levels to survival.
Specifically, a high expression of IFNwas associated with better survival while a similar trend was visible for IL-17 ( Fig. 5J and 5K ). Combinations of 2-3 cytokines did not result in better separation of the survival curves ( Supplementary Fig. S8C-S8G ).
In combination with the above, these data suggest that a dense infiltration of HPV16-positive OSSC with IFN/IL-17 oriented CD4+ and/or CD8+ CD161+ T-cells, including the HPV16-specific T-cells, are important for superior disease control in HPV-driven OPSCC. Therefore, we analyzed the disease-specific survival of HPV-specific T-cell responders within the group of patients with HPV16-positive OPSCC. Patients with HPV-positive OPSCC displaying an HPV-specific T-cell reaction had a 37.8-fold (95%CI= 7.1 to 199.9) higher chance to respond to therapy when compared to patients with HPV16-positive OPSCC lacking such a T-cell reaction (Fig. 6A) . Especially in stage III-IV HPV16-positive OPSCC, the local presence of an HPV16-specific T-cell response was a better prognostic parameter for a long survival after therapy than staging (Fig. 6B) 
survival between these two groups could not be attributed to a different cancer treatment (Supplementary Table 3 ). Intriguingly, also the T-and N-stage were on average lower in the immune responders ( Fig. 6C and 6D ), suggesting that HPV16-specific T-cells were especially present in patients with a better control of tumor growth.
Discussion
The improved clinical response of OPSCC patients to (chemo)radiotherapy has been associated with HPV and with a dense activated T-cell infiltrate but the role of the immune response against HPV in this still was not completely understood. Our findings demonstrate that the virallyderived E6 and E7 antigens make HPV-associated OPSCC highly visible to the immune system and unleashes an intratumoral HPV-specific T-cell response. These cells are poly-functional, detected among TIL in many of the patients, and have the CD161+ phenotype often found in acute rejection processes. They may locally facilitate the development of a clinically favorable tumor microenvironment because their presence is associated with a stronger influx of type 1 oriented CD4+ and CD8+ T-cells, as well as DCs and DC-like macrophages. Moreover, they produce cytokines which synergize with the platinum-based chemotherapy used to treat these patients and their detection is highly predictive for the response of patients to (chemo)radiotherapy.
HPV-specific CD4+ and CD8+ T-cells were detected in 64% of the TIL derived from HPV16-positive OPSCC, with a predominance of HPV-specific CD4+ T-cells, a result that closely matches an earlier study (35). We show that these HPV-specific tumor-infiltrating T-cells as well as the other TIL predominantly produced IFN and IL-17, suggesting the presence of Th1 and Th17 cells. In view of the accepted roles of Th1/Th17 CD4+ and CD8+ T-cells in tumor control (36, 37) , the detection of Indeed, CD161 was among the top 10 of tumor leukocyte associated genes associated with positive prognosis for many human tumors (45) . In our study CD161 was expressed by tumor-specific IFN-and/or TNF-producing CD4+ T-cells, higher frequencies of CD161 expressing CD4+ T-cells were detected in T-cell inflamed tumors and, finally, in the TCGA database the expression between CD161 and CD4 or CD8 was highly correlated and a high expression of these three genes was associated with a survival advantage for HPV16-positive OPSCC patients. Interestingly, mass cytometry showed that part of the CD8+CD103+ T-cells also expressed CD161.
In a large meta-analysis in head and neck cancer (MACH-NC) patients treated with radiotherapy alone have an overall 5-year survival of 27.2% whereas in patients receiving concomitant cisplatin chemotherapy and radiotherapy an improvement in overall survival of 6.5% is 
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Research. antibody or the combination of this antibody with IFN. The IL-12p70 production (in pg/ml; mean ± SEM) is depicted. Non-stimulated cells (moDC) were taken along as negative control. F, As in E for the 5 healthy donors showing the production of CXCL9 and CXCL10 (in pg/ml; mean ± SEM) by these myeloid cells. NS, not significant; *P<0.05; **P<0.01 and ***P<0.001. expression of two indicated genes versus all others based on the median expression levels of G, CD103 and CD8, H, CD161 and CD4, I, CD161 and CD8. J and K, As in C-F for the expression of J, IFN and K, IL-17A. All graphs, the Hazard Ration (HR) with the 95% confidence interval (CI95%) as well as the log-rank test P value is given. NS, not significant; *P<0.05; **P<0.01 and ***P<0.001. 
